Work

Drug Allergy Practice Parameter Updates to Incorporate Into Your Clinical Practice

Year: 2022

Type: article

Source: The Journal of Allergy and Clinical Immunology In Practice

DOI: 10.1016/j.jaip.2022.12.002

Authors: Aleena Banerji, Roland Solensky, Elizabeth J. Phillips, David A. Khan

Institutions: Harvard University, Massachusetts General Hospital, Oregon State University, Oregon Health & Science University, Vanderbilt University Medical Center, The University of Texas Southwestern Medical Center

Language: English

Topic: Drug-Induced Adverse Reactions

Subfield: Pharmacology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, GlaxoSmithKline, National Institutes of Health, National Health and Medical Research Council, National Human Genome Research Institute, National Institute of Allergy and Infectious Diseases

Awards: Stevens-Johnson syndrome/toxic epidermal necrolysis 2021: Collaboration, Innovation and Community, Genetic risk and long-term outcomes associated with Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in survivors, Immune Tolerance Network, Immune-mediated adverse drug reactions to HIV and TB treatments in South Africa: predict, prevent and improve long-term outcomes (IMARI SA study), NATIENS: A Phase III Randomized Double Blinded Study to Determine the Mechanisms and Optimal Management of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

OpenAlex ID: W4312084084

FWCI: 3.591

Cites: 119

Cited by: 30

Related to: 10